✦ LIBER ✦

Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C

✍ Scribed by Olle Reichard; Gunnar Norkrans; Aril Frydén; Jean-Henrik Braconier; Anders Sönnerborg; Ola Weiland

Book ID: 117310761
Publisher: The Lancet
Year: 1998
Tongue: English
Weight: 77 KB
Volume: 351
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(97)06088-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled Trial of Interferon Alfa2a With and Without Amantadine as Initial Treatment for Chronic Hepatitis C

✍ Stefan Zeuzem; Gerlinde Teuber; Uta Naumann; Thomas Berg; Jochen Raedle; Susanne 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

High-dose interferon-alpha induction tre

High-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in congenital coagulation disorders. A randomised, double-blind, placebo-controlled clinical trial

✍ K. Meijer; M.C. Kappers-Klunne; I.R.O. Novakova; E.P. Mausser-Bunschoten; M.M.W. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 320 KB

Interferon-α2bInduction Treatment with o

Interferon-α2bInduction Treatment with or Without Ribavirin in Chronic Hepatitis C: A Multicenter, Randomized, Controlled Trial

✍ Hakan Senturk; Galip Ersoz; Resat Ozaras; Sabahattin Kaymakoglu; Hakan Bozkaya; 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 389 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled clinical trial of high-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in hemophilia

✍ K. Meijer; E. B. Haagsma; J. Van Der Meer; for the CHARIBDIS Study Group 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant α-interferon for chronic non-A, non-B hepatitis

✍ Masao Omata; Yoshimi Ito; Osamu Yokosuka; Fumio Imazeki; Masami Tagawa; Susumu T 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 527 KB

Combination therapy with thymosin α1 and

Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial

✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr